by McKesson Ventures | Feb 22, 2018 | Portfolio News
A new report from Healthcare Market Research Reports has been published that explores the market potential related to diagnostic, monitoring, and screening test opportunities for circulating tumor cell, cell-free DNA, and exosome/microvesicle cancer diagnostics by...
by McKesson Ventures | Jan 27, 2018 | Portfolio News
GRAIL management has confirmed that the company will be releasing a cell-free, DNA-based assay in Hong Kong this year to test for nasopharyngeal carcinoma. At the recent Precision Medicine World Conference, GRAIL also outlined their strategy for a circulating...
by McKesson Ventures | Dec 15, 2017 | Press Releases
GRAIL, Inc., a McKesson Ventures portfolio company whose mission is to detect cancer early when it can be cured, announced on December 14th the appointment of Jennifer Cook as Chief Executive Officer, effective January 2nd, 2018. Bill Rastetter, the interim CEO since...
by McKesson Ventures | Nov 29, 2017 | Portfolio News
In March 2017, life sciences startup GRAIL announced that it had raised $900 million in Series B funding. The newly acquired investment capital puts GRAIL one step closer toward its goal of developing a blood test that can detect early signs of cancer. Founded in 2016...
by McKesson Ventures | Nov 10, 2017 | Portfolio News
LinkedIn’s new startup-focused edition of the LinkedIn Top Companies lists the 50 companies most attractive to workers and venture capitalists. Although most of the companies on LinkedIn’s list hail from the San Francisco Bay Area, a third of the companies on the list...
